Clinical Significance of Protocol Biopsy Soon after Renal Transplantation.
10.4285/jkstn.2011.25.4.264
- Author:
Seung Young OH
1
;
Sang Il MIN
;
Sanghyun AHN
;
Suh Min KIM
;
Daedo PARK
;
Taejin PARK
;
Kyung Chul MOON
;
Jongwon HA
;
Sang Joon KIM
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. sjkimgs@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Protocol biopsy;
Subclinical rejection (SCR);
Renal transplantation
- MeSH:
Antibodies, Monoclonal;
Biopsy;
HLA-DR Antigens;
Humans;
Kidney Transplantation;
Multivariate Analysis;
Recombinant Fusion Proteins;
Rejection (Psychology);
Risk Factors;
Transplantation, Homologous
- From:The Journal of the Korean Society for Transplantation
2011;25(4):264-269
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Several studies reported that sub-clinical rejection (SCR) detected by a protocol biopsy soon after renal transplantation does permanent damage to a renal allograft, contributing to chronic allograft nephropathy (CAN). This article investigated the risk factors involved in SCR and the effects of treating SCR, and evaluated the clinical significance of a protocol biopsy soon after renal transplantation. METHODS: From January 2007 to June 2010, 253 patients received renal transplantation. Patients were divided into two groups according to whether or not they had undergone a protocol biopsy. To analyze the effect of SCR treatments, patients who were diagnosed with SCR were divided into two groups according to whether or not they had been treated with SCR. The patients who did not undertake a protocol biopsy were included in the untreated groups. RESULTS: Among 138 patients who undertook protocol biopsies, 65 patients (47.1%) showed SCR. In univariate analysis, both the number of HLA-DR mismatches (P=0.003) and not using Simulect (P=0.01) were identified as risk factors of SCR. In multivariate analysis, not using Simulect (P=0.006) was identified as an risk factor independent of SCR. deltaGFR, subtracting GFR at 1 week from GFR at that point, showed significant differences between SCR-treated patients and untreated patients at 1, 3, 6, 9, 12, 24, and 36 months with a P value of less than 0.05. CONCLUSIONS: A protocol biopsy can detect SCR, especially in patients with risk factors such as a high number of HLA mismatches or not using Simulect. Treatment of SCR detected by protocol biopsy will help to improve long-term renal function.
